57712-67-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2,4(1H,3H)-Pyrimidinedione, 5-bromo-1-(phenylmethyl)is used as a research compound for its potential biological activities and medicinal properties. Its unique structure and functional groups contribute to its potential applications in the development of new drugs for the treatment of various diseases and medical conditions.
Used in Anti-cancer Applications:
In the field of oncology, 2,4(1H,3H)-Pyrimidinedione, 5-bromo-1-(phenylmethyl)is studied for its potential anti-cancer properties. It may exhibit inhibitory effects on tumor growth and progression, making it a promising candidate for the development of novel cancer therapeutics.
Used in Anti-inflammatory Applications:
2,4(1H,3H)-Pyrimidinedione, 5-bromo-1-(phenylmethyl)is also being investigated for its potential anti-inflammatory properties. It may help in the management of inflammation-related conditions by modulating the immune response and reducing inflammation.
Used in Anti-viral Applications:
2,4(1H,3H)-Pyrimidinedione, 5-bromo-1-(phenylmethyl)is being explored for its potential anti-viral properties. It may have the ability to inhibit viral replication and reduce the severity of viral infections, offering a new avenue for the development of antiviral drugs.
Used in the Development of New Drugs for Various Diseases and Medical Conditions:
Due to its diverse potential applications, 2,4(1H,3H)-Pyrimidinedione, 5-bromo-1-(phenylmethyl)is being studied for its potential use in the development of new drugs for the treatment of a wide range of diseases and medical conditions. Its unique structure and functional groups may provide new insights and opportunities for drug discovery and therapeutic intervention.

Upstream product

• 716-99-4 1-benzyl-dihydro-pyrimidine-2,4-dione 
• 51-20-7 5-bromouracil 
• 100-39-0 benzyl bromide 
• 99983-49-0 1-benzyl-5,5-dibromo-dihydro-pyrimidine-2,4-dione 

Downstream Products

• 1257939-93-7 1-benzyl-5-bromo-2-oxo-1,2-dihydropyrimidin-4-yl 2,4,6-triisopropylbenzenesulfonate 
• 717-00-0 1-benzyluracil 
• 1597448-73-1 1-N-benzyl-5-(fur-2-yl)uracil 
• 61686-79-1 1-benzyl-3-methyl-2,4-pyrimidinedione 
• 1597448-69-5 1-N-benzyl-5-phenyluracil 
• 1597448-86-6 1-N-benzyl-6-(4-methoxyphenyl)uracil 
• 1597448-72-0 1-N-benzyl-5-(4-methoxyphenyl)uracil 

Relevant academic research and scientific papers

The evaluation of 5-amino- and 5-hydroxyuracil derivatives as potential quadruplex-forming agents

5-Substituted uracils (NH2 or OH groups in position 5) have been examined theoretically and experimentally as potential building blocks in quadruplex structures. Our high level Density Functional Theory (DFT) calculations showed that the tetram

Noncovalent and site-directed spin labeling of nucleic acids

Spin label parking: The rigid spin label c (magenta), which is an analogue of cytidine, binds site-specifically to abasic sites in duplex DNAs, through hydrogen bonding to guanine (blue) and π stacking with the flanking base pairs. EPR spectroscopy shows

Macrocyclic 5-bromouracil derivatives: synthesis and transformation of a uracil ring

Cyclization of 1,3-bis(ω-bromoalkyl)-5-bromouracil with p-methoxybenzylamine or sodium sulfide led to a series of pyrimidinophanes containing heteroatoms in bridges. An unusual behaviour of the 5-bromouracil ring, namely its contraction into hydantoin units during the cyclization reactions with p-methoxybenzylamine was observed. Sodium sulfide does not affect the 5-bromouracil ring, and no transformation products were observed in the synthesis of pyrimidinophanes with sulfur bridges. A possible reaction mechanism is given.

Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents

Molecule responding to formula (I): and its use for the preparation of a medicament for the prevention and/or treatment of a pathology caused by a mycobacteria

Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists

Novel pyrimidinedione compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1aadrenergic receptor antagonists is also described. One application of these compounds is in the treatmen